Helicobacter pylori and gastroesophageal reflux disease: To treat or not to treat?

Scandinavian Journal of Gastroenterology

Volumn 36, Issue 7, 2001, Pages 677-682

  O'Connor, H J ^a   O'Morain, C A ^a  

^a Tullamore General Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

DRUG EFFICACY; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0034977556     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655201300191923     Document Type: Review

References (74)

1. Gastroesophageal reflux disease: The role of motility in pathophysiology and therapy
2. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety
3. Changing patterns of H. pylori gastritis in long-standing acid suppression
4. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
5. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
6. In a world of black and white, Helicobacter pylori is gray
7. Helicobacter pylori and gastro-oesophageal reflux disease - Clinical implications and management
8. Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine
9. Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease? A randomised double blind study
10. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux
11. Gastric precancerous process in a high risk population: Cohort follow-up
12. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
13. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole
14. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
15. Lack of effect of acid suppression therapy on gastric atrophy
16. Atrophy, acid suppression and Helicobacter pylori infection: A tale of two studies
17. Long-term sequelae of Helicobacter pylori gastritis
18. Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics
19. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment
20. H. pylori eradication for chronic gastritis during omeprazole therapy for GERD
21. Opposing time trends of peptic ulcer and reflux disease
22. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis
23. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: A case-control study
24. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
25. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease
26. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease
27. Corpus gastritis is protective against reflux oesophagitis
28. H. pylori and cagA: Relationships with gastric cancer, duodenal ulcer and reflux esophagitis and its complications
29. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus - Evaluation of 24-h pH monitoring
30. Is there a role for Helicobacter pylori in gastroesophageal reflux disease? A 24 hour ambulatory combined pH and manometry study
31. Impact of Helicobacter pylori infection on gastroesophageal reflux
32. Manometric and pH-metric findings in GERD with and without H. pylori infection
33. Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease
34. No occurrence of reflux oesophagitis following Helicobacter pylori eradication in duodenal ulcer patients - A 5 year endoscopic follow-up in South-East Asian patients
35. The appearance of GORD in patients with duodenal ulcer after eradication of Helicobacter pylori (Hp) infection: A 4-year prospective study
36. Different prevalences of reflux oesophagitis and hiatus hernia among dyspeptic patients in England and Singapore
37. Ethnic differences in gastro-oesophageal reflux disease
38. Does cure of Helicobacter pylori infection induce heartburn?
39. No increase of reflux symptoms or esophagitis in patients with nonulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomised double-blind placebo-controlled trial
40. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer
41. The association of oesohagitis with disease in the stomach and duodenum
42. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia
43. Prevalence of gastrooesophageal reflux disease (GORD) in H. pylori-positive peptic ulcer disease and the impact of eradication therapy
44. Symptomatic benefit 1-3 years post H. pylori eradication in ulcer patients: Impact of reflux disease
45. Duodenal ulcer and GORD: Unmasking the troth
46. GERD symptoms preexist and do not appear after H. pylori eradication for duodenal ulcer
47. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma
48. Is Helicobacter pylori (HP) associated with adenocarcinoma (AC) of the esophagus?
49. Barrett's esophagus and the presence of Helicobacter pylori
50. Helicobacter pylori infection and adenocarcinoma arising in Barrett's esophagus
51. Bloodgroup phenotypes, sulfomucins and Helicobacter pylori in Barrett's esophagus
52. Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer
53. Absence of Campylobacter-like organisms in Barrett's esophagus
54. Organismos tipo Campylobacter en el esofago de Barrett
55. Barrett's oesophagus and Heliciobacter pylori
56. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus
57. Evaluation of Helicobacter pylori in reflux oesphagitis and Barrett's oesophagus
58. Short Barrett: Prevalence and risk factors
59. The incidence of premalignant markers of esophageal cancer is increased in Barrett's patients with Helicobacter pylori (Hp)
60. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: Prevalences and associations with endoscopic erosive oesophagitis and gastritis
61. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease
62. Patterns of gastritis in patients with gastro-oesophageal reflux disease
63. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients
64. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects
65. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
66. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients
67. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects
68. Does H. pylori infection influence the response to treatment with acid inhibition in patients with gastroesophageal reflux disease (GERD)?
69. Gastric Helicobacter pylori infection accelerates healing of reflux oesophagitis during treatment with the proton-pump inhibitor pantoprazole
70. Relapse prevention in reflux esophagitis with regard to HP-status: Double-blind, randomized multicenter trial to compare the effectiveness of pantoprazole versus ranitidine
71. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy
72. Natural history of reflux oesophagitis: A 10 year follow up of its effect on patient symptomatology and quality of life
73. Helicobacter pylori, GERD, NSAIDs and cancer: Where we really stand
74. Helicobacter gastroduodenitis: A serious infectious disease